Congress may be busy investigating Mylan and its EpiPen pricing, but that doesn’t mean its watchdog committees can’t turn a spotlight on pharmacy benefits managers, too.
After Mylan CEO Heather Bresch blamed PBMs for “incentivizing” price increases, pharmacists–including Rep. Buddy Carter, the only pharmacist in Congress–are calling for more scrutiny.
The National Community Pharmacists Association urged the House Committee on Oversight and Government Reform to investigate PBMs, which manage formularies and negotiate drug discounts for insurers. Mylan has said that PBM rebates account for almost half of EpiPen’s $600-plus list price.
By Tracy Staton in Fierce Pharma